Impact of Samrakshan Program in Pregnant Women
International Journal of Medicine & Health Research (IJMHR) (ISSN 2395-3586) · 20.09.2026 · 14 · 1-8
DOI: 10.71393/jzxpya75 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medicine & Health Research (IJMHR) (ISSN 2395-3586), online erschienen am 20.09.2026. Verfasst von Sikandar Khan und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction: Perinatal mortality remains a major challenge in India. The IRIA-initiated Samrakshan Programme integrates trimester-specific fetal Doppler with antenatal ultrasonography for early detection of pre-eclampsia, FGR, and other high-risk conditions. Aim & objective: This study evaluated the impact of the Samrakshan Programme on maternal and perinatal outcomes among high-risk pregnancies attending Gajra Raja Medical College (GRMC), Gwalior. Material & Methods: 36 first-trimester high-risk pregnant women meeting predefined inclusion and exclusion criteria. Participants underwent trimester-specific Doppler evaluation, including uterine artery, umbilical artery, middle cerebral artery, cerebroplacental ratio (CPR) assessments. Women identified as high risk for preterm pre-eclampsia received low-dose aspirin prophylaxis. Maternal and fetal outcomes were analyzed using SPSS version 25, with p
Zitieren
APA
Khan, S., Gupta, A., & Sharma, L. K. (2026). Impact of Samrakshan Program in Pregnant Women. International Journal of Medicine & Health Research (IJMHR) (ISSN 2395-3586), 14, 1-8. https://doi.org/10.71393/jzxpya75
Vancouver
Khan S, Gupta A, Sharma LK. Impact of Samrakshan Program in Pregnant Women. International Journal of Medicine & Health Research (IJMHR) (ISSN 2395-3586). 2026;14:1-8. doi:10.71393/jzxpya75
BibTeX
@article{Khan2026,
author = {Khan, Sikandar and Gupta, Akshara and Sharma, L K},
title = {Impact of Samrakshan Program in Pregnant Women},
journal = {International Journal of Medicine & Health Research (IJMHR) (ISSN 2395-3586)},
year = {2026},
volume = {14},
pages = {1--8},
doi = {10.71393/jzxpya75}
}
EUVIMED